Tokai Pharmaceuticals Inc. (TKAI) Shares Down 0.9%
Tokai Pharmaceuticals Inc. (NASDAQ:TKAI) shares dropped 0.9% during mid-day trading on Friday . The stock traded as low as $5.39 and last traded at $5.47, with a volume of 55,727 shares changing hands. The stock had previously closed at $5.52.
A number of brokerages recently commented on TKAI. Janney Montgomery Scott began coverage on Tokai Pharmaceuticals in a report on Wednesday, April 6th. They set a “buy” rating on the stock. Bank of America Corp. began coverage on Tokai Pharmaceuticals in a report on Wednesday, April 6th. They set a “buy” rating and a $16.00 price target on the stock. Finally, BMO Capital Markets began coverage on Tokai Pharmaceuticals in a report on Monday, April 11th. They set an “outperform” rating and a $11.00 price target on the stock. One research analyst has rated the stock with a sell rating and five have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $18.00.
The stock’s market cap is $121.78 million. The stock’s 50 day moving average is $6.32 and its 200 day moving average is $6.54.
Tokai Pharmaceuticals (NASDAQ:TKAI) last announced its earnings results on Tuesday, May 10th. The biopharmaceutical company reported ($0.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.50) by $0.01. Equities research analysts predict that Tokai Pharmaceuticals Inc. will post ($2.00) EPS for the current year.
Tokai Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on developing and commercializing therapies for the treatment of prostate cancer and other hormonally-driven diseases. The Company’s lead drug candidate, galeterone, is an oral small molecule that utilizes the mechanistic pathways of second-generation androgen signaling inhibitors, while also introducing a third mechanism-androgen receptor degradation.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.